IDEV - ETF AI Analysis
Top Page
iShares Core MSCI International Developed Markets ETF (IDEV)
Rating:66Neutral
Price Target:―
Positive Factors
Broad Country Diversification
The ETF spreads its investments across many developed markets like Japan, the UK, Europe, Canada, and Australia, which helps reduce the impact of problems in any single country.
Low Expense Ratio
The fund charges a very low annual fee, so more of the investment returns stay in investors’ pockets over time.
Generally Strong Recent Performance
The ETF has shown solid gains so far this year and in recent months, suggesting its mix of international stocks has been working well lately.
Negative Factors
Limited U.S. Market Exposure
Because the ETF focuses on international developed markets and only has a small slice in the U.S., investors relying on it alone may miss out on parts of the U.S. stock market’s performance.
Mixed Results Among Top Holdings
While several of the largest positions have been strong performers, a few key names have been weak, which can drag on overall returns.
Heavy Financial Sector Weight
A sizable portion of the fund is invested in financial companies, which can make the ETF more sensitive to changes in interest rates and banking conditions.
IDEV vs. SPDR S&P 500 ETF (SPY)
AUM29.05B
RegionDeveloped Markets
Expense Ratio0.04%
Beta0.75
IssueriShares
Inception DateMar 21, 2017
Dividend Yield3.26%
Asset ClassEquity
Index TrackedMSCI World ex USA IMI
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume1,189,772
30 Day Avg. Volume2,010,884
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
99.42Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2225
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IDEV Summary
IDEV is an ETF that tracks the MSCI World ex USA IMI index, which means it invests in thousands of companies from developed countries outside the U.S. and Canada, such as Japan, the UK, and Europe. It holds well-known names like Nestlé and AstraZeneca, and spreads money across many sectors including financials, industrials, and health care. Someone might invest in IDEV to diversify beyond the U.S. stock market and tap into long-term growth in other developed economies. A key risk is that international stocks can go up and down with global markets and currency swings.
How much will it cost me?The iShares Core MSCI International Developed Markets ETF (IDEV) has an expense ratio of 0.04%, meaning you’ll pay $0.40 per year for every $1,000 invested. This is lower than average because it’s a passively managed fund that tracks an index, which typically costs less to operate compared to actively managed funds.
What would affect this ETF?Positive drivers for IDEV could include economic growth in developed markets outside the U.S., particularly in sectors like financials, technology, and healthcare, which are heavily represented in the ETF. However, negative factors such as rising interest rates or geopolitical tensions in Europe and Asia could impact the performance of key holdings like ASML, Nestlé, and HSBC, as well as broader sector trends like energy and industrials. Regulatory changes or currency fluctuations in these regions may also affect returns.
IDEV Top 10 Holdings
IDEV’s story is all about broad developed-markets exposure with a few clear stars setting the pace. Dutch chip-equipment giant ASML has been rising steadily this year, giving the fund a tech-powered tailwind, while global banks like HSBC and Royal Bank of Canada are also pulling their weight as financials stay in favor. Health care is a quiet backbone here: AstraZeneca and Novartis are ticking along, even as Roche has been more mixed and occasionally drags. With holdings spread across Europe, the U.K., and Asia-Pacific, the fund avoids any single-country or single-sector obsession.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ASML Holding NV | 1.93% | $559.63M | €477.33B | 106.32% | 76 Outperform | |
| HSBC Holdings | 1.08% | $312.87M | £226.99B | 58.35% | 80 Outperform | |
| AstraZeneca | 1.02% | $295.27M | $292.69B | 32.74% | 80 Outperform | |
| Roche Holding AG | 1.00% | $289.90M | $327.04B | 22.13% | 73 Outperform | |
| Novartis AG | 0.96% | $278.49M | CHF207.57B | 22.14% | 80 Outperform | |
| Nestlé SA | 0.92% | $266.71M | CHF205.30B | -1.29% | 71 Outperform | |
| Shell (UK) | 0.87% | $252.83M | £184.86B | 32.32% | 73 Outperform | |
| Royal Bank Of Canada | 0.86% | $249.86M | $245.63B | 48.99% | 75 Outperform | |
| Siemens | 0.79% | $227.57M | €185.31B | 21.53% | 74 Outperform | |
| Commonwealth Bank of Australia | 0.73% | $210.95M | AU$291.71B | 6.28% | 64 Neutral |
IDEV Technical Analysis
Neutral
―
Price Trends
86.42
Positive
85.45
Positive
81.59
Positive
Market Momentum
0.69
Positive
51.09
Neutral
24.74
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IDEV, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 87.30, equal to the 50-day MA of 86.42, and equal to the 200-day MA of 81.59, indicating a neutral trend. The MACD of 0.69 indicates Positive momentum. The RSI at 51.09 is Neutral, neither overbought nor oversold. The STOCH value of 24.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IDEV.
IDEV Peer Comparison
Comparison Results
Performance Comparison
IDEV
iShares Core MSCI International Developed Markets ETF
86.23
17.11
24.75%
VEA
Vanguard FTSE Developed Markets ETF
―
―
―
SCHF
Schwab International Equity ETF
―
―
―
SPDW
SPDR Portfolio Developed World ex-US ETF
―
―
―
DFAI
Dimensional International Core Equity Market ETF
―
―
―
AVDE
Avantis International Equity ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents